Clinical trials: Prostate Cancer, Castration Resistant
Prostate Cancer
Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data
We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated machine vision based image analysis of…
- Trial name
- NCT00578409
- Where
- United States
- Volunteers
- 758 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite…
- Trial name
- NCT06526299
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Washington
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
This phase I trial studies the side effects and best dose of niclosamide when given together with enzalutamide in treating patients with castration resistant prostate cancer that has spread from the primary site to other places…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma
- Trial name
- NCT02532114
- Testing
- Enzalutamide, Laboratory Biomarker Analysis, Niclosamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Prostatic Neoplasms, Castration-Resistant
A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway…
- Trial name
- NCT07677267
- Where
- United States
- Volunteers
- 1,067 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer
Intestinal Akkermansia Muciniphila in Prostate Cancer
Prostate cancer has the highest incidence and is the second leading cause of cancer death in men in western countries. Androgen deprivation therapy is the backbone treatment.
- Trial name
- AkkPRO (NCT06242509)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
This phase II trial studies the side effects of ESK981 and nivolumab and to see how well they work for the treatment of castration resistant prostate cancer that has spread to other places in the body (metastatic).
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT04159896
- Testing
- Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Metastatic Castration-resistant Prostate Cancer
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.
- Trial name
- Rad2Nivo (NCT04109729)
- Testing
- Nivolumab, Radium-223
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Utah
Neoplasm, Prostate Cancer
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety, tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with metastatic castration-resistant prostate cancer…
- Trial name
- NCT02747342
- Testing
- SHR3680; SHR3162
- Where
- 6 sites in Australia
- Volunteers
- 33 people
- Sponsor
- Atridia Pty Ltd.
Prostatic Neoplasms
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3…
- Trial name
- NCT01934790
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 16 sites in United States, Finland and 5 more
- Volunteers
- 45 people
- Sponsor
- Bayer
m CRPC
Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK（pharmacokinetics） and PD（pharmacodynamics） of HSK46575 when given orally in patients with metastatic castration-resistant…
- Trial name
- NCT07007910
- Testing
- HSK46575
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Cancer
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone
This study is being conducted to characterize the safety and recommended phase 2 dose (RP2D) of combining afuresertib, independently with 2 approved drugs: enzalutamide (Xtandi®, "Xtandi is a trademark of Astellas Pharma, Inc." )…
- Trial name
- NCT02380313
- Testing
- Afuresertib, Enzalutamide, Abiraterone
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Castration Resistant Prostate Cancer (CRPC)
A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects
A study to evaluate the bioavailability (BA) of a single oral dose of MDV3100 (enzalutamide) formulated as a solid spray dried tablet compared to oral liquid-filled capsules, and the safety and tolerability of oral formulations.
- Conditions
- Healthy Subjects, Castration Resistant Prostate Cancer (CRPC), Relative Bioavailability, MDV3100
- Trial name
- NCT01911741
- Testing
- MDV3100
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer, Prostatic Neoplasms
Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this observational study is to learn which factors can predict how well lutetium-177 PSMA therapy works in people with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastases
- Trial name
- NCT07863986
- Testing
- [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry
- Where
- Lithuania
- Volunteers
- 70 people
- Sponsor
- Lithuanian University of Health Sciences
Metastatic Castration-resistant Prostate Cancer
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05917470
- Testing
- ONCT-534
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 21 people
- Sponsor
- Oncternal Therapeutics, Inc
Prostate Cancer Metastatic
Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer
The skeleton is the most frequent organ of distal metastases in prostate cancer, often representing the only site of metastatic disease.
- Trial name
- iPROMET (NCT05078151)
- Testing
- Whole-Body Diffusion Weighted MRI
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Prostatic Neoplasms
Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+Abiraterone
PROCeed is an observational study assessing real world clinical endpoints and demographic characteristics in patients with castration-resistant prostate cancer treated with Olaparib+Abiraterone.
- Trial name
- PROCeed-BR (NCT06457854)
- Where
- 5 sites in Brazil
- Sponsor
- AstraZeneca
Prostatic Neoplasms, Castration-Resistant
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the effects of repeat dosing of JNJ-56021927 on the pharmacokinetics for single-dose multiple cytochrome P450 (CYP450) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2C8) and transporter (P-gp and…
- Trial name
- NCT02592317
- Testing
- JNJ 56021927, Drug Cocktail, Pioglitazone
- Where
- 3 sites in Moldova, Spain
- Volunteers
- 23 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer.
- Trial name
- NCT02788773
- Testing
- Durvalumab, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 52 people
- Sponsor
- Canadian Cancer Trials Group
Prostate Neoplasms
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT01228760
- Testing
- ASG-5ME
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.